Cidara Therapeutics announced Monday that J&J’s Janssen subsidiary will license the San Diego-based company’s universal influenza antiviral conjugate (AVC) technology—shelling out $27 million upfront (plus up to $753 million in milestone payments) for exclusive development and commercialization rights for Cidara’s CD388 and other influenza AVCs.

The novel immunotherapies have the potential to prevent and treat “all seasonal and pandemic” flu strains, according to Cidara’s press…